Longer screening intervals are recommended following a negative HPV test in primary cervical screening

Pooled results of four randomised controlled trials in Europe showed that HPV testing reduces cervical cancer risk. 1 The British ARTISTIC trial 2 and several other studies have also shown that it gives longer protection for cervical intraepithelial neoplasia grade 3 (CIN3). The primary aim of cervi...

Full description

Saved in:
Bibliographic Details
Published inBMJ evidence-based medicine Vol. 22; no. 5; p. 178
Main Authors Peto, Julian, Gilham, Clare
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.10.2017
Subjects
Age
Cellular biology
Cervical cancer
Cervical Intraepithelial Neoplasia
Early Detection of Cancer
Female
Health risk assessment
Human papillomavirus
Humans
Infections
Mass Screening
Medical screening
Uterine Cervical Neoplasms
United Kingdom > UK
Netherlands
Europe
Online AccessGet full text

Cover

More Information
Summary:Pooled results of four randomised controlled trials in Europe showed that HPV testing reduces cervical cancer risk. 1 The British ARTISTIC trial 2 and several other studies have also shown that it gives longer protection for cervical intraepithelial neoplasia grade 3 (CIN3). The primary aim of cervical screening is to prevent cancer, and the 22 cancers observed among HPV negative women in this very large study, suggesting an invasive cancer risk of the order of 1 in 1000 after a 10-year screening interval, are a major addition to the evidence. Collaborative pooling of data and modelling studies are needed to estimate the effects on early and advanced cancer incidence of HPV testing with screening intervals of up to 10 years at different ages, and particularly at a woman's final HPV test.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1356-5524
2515-446X
1473-6810
2515-4478
DOI:10.1136/ebmed-2016-110625